Literature DB >> 21888827

Highly virulent Escherichia coli O26, Scotland.

Kevin G J Pollock, Sheetal Bhojani, T James Beattie, Lesley Allison, Mary Hanson, Mary E Locking, John M Cowden.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21888827      PMCID: PMC3322084          DOI: 10.3201/eid1709.110199

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, microthrombi, and multiorgan injury. HUS is one of the commonest causes of acute renal failure in children worldwide and is most frequently precipitated by infection with verotoxin-producing Escherichia coli (VTEC) such as E. coli O157 (). However, non-O157 VTEC serotypes have been increasingly found in the development of HUS (–). Although previous surveillance of childhood HUS in Scotland identified E. coli O157 in >90% of cases, non-O157 serotypes have also been associated with HUS (). In 2010, several particularly severe cases of HUS were reported to Health Protection Scotland by a consultant pediatric nephrologist. Subsequent tests identified the pathogen in these cases as E. coli O26. However, in a recent study of pediatric HUS cases in Europe, children infected with E. coli O26 did not exhibit different clinical signs and symptoms from patients infected with other VTEC serotypes (). To establish whether the host pathophysiologic responses to E. coli O157 and E. coli O26 strains differed, we analyzed a cohort of children with HUS who were infected with these VTEC serotypes. In Scotland, most patients with pediatric thrombotic microangiopathy are referred to a specialist pediatric hospital, which immediately reports cases of HUS to Health Protection Scotland as part of national surveillance. To test the hypothesis that E. coli O26 was more virulent than E. coli O157, we performed an age-matched, nested case–case study of HUS patients and compared host clinical markers, treatment, and outcomes from pediatric cases in 2010. Data collection has been described elsewhere (). The statistical significances of associations between categorical variables were investigated by using χ2, Fisher exact, Mann-Whitney, or t tests. All analyses were performed by using SPSS version 11 (SPSS Inc., Chicago, IL, USA) with a significance level of 5%. Although initial signs and symptoms were similar for both sets of cases, i.e., bloody diarrhea and abdominal pain, statistical analysis showed that children with O26-HUS were more likely to have neurologic complications and diabetes mellitus and require admission to the intensive care unit than O157-HUS patients (p = 0.02 for neurologic complications and diabetes and p = 0.04 for admission to an intensive treatment unit; Table).
Table

Characteristics of infection in children with Escherichia coli O157 versus E. coli O26, Scotland, 2010*

VariableO157 HUS, n = 12O26 HUS, n = 3p value
Age, y
4.5 ± 1.0
3.7 ± 1.3

Clinical signs and symptoms
Diarrhea123
Bloody diarrhea8 (67)2 (67)NS
Abdominal pain8 (67)3 (75)NS
Fever2 (17)1 (33)NS
Neurologic involvement3 (25)3 (100)0.02
Diabetes1 (12)2 (67)0.02
Cardiomyopathy01 (33)0.04
Anuria, d
7.7 ± 2.4
15.7 ± 1.3
0.04
Clinical parameters
Leukocyte count × 109/L42.1 ± 14.425.9 ± 4.8NS
C-reactive protein, mg/L93.5 ± 28.4151 ± 74NS
Serum albumin, g/L22.5 ± 1.322.3 ± 2.4NS
Lactate dehydrogenase, IU/L
2,521 ± 362
1,991 ± 642
NS
Admission to ITU3 (25)3 (100)0.04
Duration of hospitalization, d
13.2 ± 2.2
25 ± 3.8
0.03
Treatment
Peritoneal dialysis, d7.4 ± 1.910NS
Hemodialysis, d8.5 ± 1.58.3 ± 3.0NS
Hemofiltration03 (100)0.001
Laparotomy
0
1 (33)
0.04
Postdischarge hypertension02 (67)0.01

*Values are mean ± SE or no. (%). Significance relates to difference between groups. HUS, hemolytic uremic syndrome; NS, not significant, ITU, intensive treatment unit.

*Values are mean ± SE or no. (%). Significance relates to difference between groups. HUS, hemolytic uremic syndrome; NS, not significant, ITU, intensive treatment unit. All patients with HUS were oligoanuric, and the 2 groups did not differ with respect to this parameter. However, O26-HUS patients had significantly longer periods of anuria than O157-HUS patients (p = 0.04; Table) and were more likely to require treatment with hemofiltration than with peritoneal or hemodialysis (p = 0.001; Table). One patient with O26-HUS also experienced cardiomyopathy resulting in reduced left ventricular function. Our study illustrates the potential for increased severity of E. coli O26 infection in children. In Scotland, HUS is more commonly associated with E. coli O157 infection, and the outcome for children infected with this pathogen is much better than that reported in other studies (,). In this study, the clinical severity and outcomes for the children with O26-HUS were worse than for children requiring treatment for O157-HUS. We investigated the prehospital management of E. coli O157 and O26 patients in this cohort and found no difference in pharmacologic intervention or duration of delay in admission to hospital. In our cohort, vtx and vtx genes were detected in isolates from 2 of 3 patients. A diagnosis was made in the third patient by detection of E. coli O26 lipopolysaccharide–specific immunoglobulin M in serum; it was therefore not possible to confirm the presence of vtx genes. However, it is not unusual for VTEC to be undetectable in stool samples from patients with HUS, most likely because of intrahost bacteriophage lysis. Therefore, serodiagnosis of VTEC is considered a necessary adjunct to bacteriological confirmation of infection (). A recent study suggests E. coli O26 exists as a highly dynamic group of organisms that can undergo verotoxin gene loss and be transferred during infection in humans, resulting in new pathogenic clones (). Therefore, vtx gene acquisition by E. coli O26 may have contributed to increased virulence. Our study was limited by the small number of patients with pediatric O26-HUS. However, given the severity of the complications experienced by the children in this cohort, we believe it is necessary to communicate these findings promptly to the international community. We suggest that infection with E. coli O26 in children can result in more severe and complicated forms of HUS than those caused by E. coli O157. In contrast to the findings of Gerber et al., we found that there was a significant difference in neurologic complications between the 2 groups (). Epidemiologic investigations found that 2 of the 3 children lived on farms and may have acquired infection while playing near their homes (the other was acquired through foreign travel). Risk communication of VTEC infection to parents of young children who live in farming communities remains problematic, perhaps because of the perception that immunity has been acquired. Although this suggestion may be true for adults, children are likely to be immunologically naive. Salient public health messages on simple precautionary behavior need to be regularly reinforced because prevention of VTEC infection prevents HUS.
  9 in total

1.  Clinical surveillance of thrombotic microangiopathies in Scotland, 2003-2005.

Authors:  K G J Pollock; D Young; T J Beattie; W T A Todd
Journal:  Epidemiol Infect       Date:  2007-03-05       Impact factor: 2.451

2.  Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation.

Authors:  Lothar-Bernd Zimmerhackl; Alejandra Rosales; Johannes Hofer; Magdalena Riedl; Therese Jungraithmayr; Alexander Mellmann; Martina Bielaszewska; Helge Karch
Journal:  Semin Thromb Hemost       Date:  2010-09-23       Impact factor: 4.180

3.  Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans.

Authors:  Martina Bielaszewska; Rita Prager; Robin Köck; Alexander Mellmann; Wenlan Zhang; Helmut Tschäpe; Phillip I Tarr; Helge Karch
Journal:  Appl Environ Microbiol       Date:  2007-03-30       Impact factor: 4.792

Review 4.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.

Authors:  Kristine E Johnson; Cheleste M Thorpe; Cynthia L Sears
Journal:  Clin Infect Dis       Date:  2006-11-09       Impact factor: 9.079

6.  Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium.

Authors:  Thomas Aldick; Martina Bielaszewska; Wenlan Zhang; Jens Brockmeyer; Herbert Schmidt; Alexander W Friedrich; Kwang S Kim; M Alexander Schmidt; Helge Karch
Journal:  Microbes Infect       Date:  2006-12-22       Impact factor: 2.700

Review 7.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Authors:  Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

8.  Human infections with verocytotoxin-producing Escherichia coli O157--10 years of E. coli O157 serodiagnosis.

Authors:  Henrik Chart; Thomas Cheasty
Journal:  J Med Microbiol       Date:  2008-11       Impact factor: 2.472

9.  Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Authors:  Angela Gerber; Helge Karch; Franz Allerberger; Hege M Verweyen; Lothar B Zimmerhackl
Journal:  J Infect Dis       Date:  2002-08-02       Impact factor: 5.226

  9 in total
  12 in total

1.  The challenge of managing hemophilia A and STEC-induced hemolytic uremic syndrome.

Authors:  Dineke Westra; Eiske M Dorresteijn; Auke Beishuizen; Lambert P W J van den Heuvel; Paul P T Brons; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2012-09-23       Impact factor: 3.714

2.  Prevalence and Epidemiology of Non-O157 Escherichia coli Serogroups O26, O103, O111, and O145 and Shiga Toxin Gene Carriage in Scottish Cattle, 2014-2015.

Authors:  Deborah V Hoyle; Marianne Keith; Helen Williamson; Kareen Macleod; Heather Mathie; Ian Handel; Carol Currie; Anne Holmes; Lesley Allison; Rebecca McLean; Rebecca Callaby; Thibaud Porphyre; Sue C Tongue; Madeleine K Henry; Judith Evans; George J Gunn; David L Gally; Nuno Silva; Margo E Chase-Topping
Journal:  Appl Environ Microbiol       Date:  2021-04-27       Impact factor: 4.792

3.  Pathogenic potential to humans of bovine Escherichia coli O26, Scotland.

Authors:  Margo E Chase-Topping; Tracy Rosser; Lesley J Allison; Emily Courcier; Judith Evans; Iain J McKendrick; Michael C Pearce; Ian Handel; Alfredo Caprioli; Helge Karch; Mary F Hanson; Kevin G J Pollock; Mary E Locking; Mark E J Woolhouse; Louise Matthews; J Chris Low; David L Gally
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

4.  The utility and public health implications of PCR and whole genome sequencing for the detection and investigation of an outbreak of Shiga toxin-producing Escherichia coli serogroup O26:H11.

Authors:  T J Dallman; L Byrne; N Launders; K Glen; K A Grant; C Jenkins
Journal:  Epidemiol Infect       Date:  2014-10-15       Impact factor: 4.434

5.  Efficient induction of comprehensive immune responses to control pathogenic E. coli by clay nano-adjuvant with the moderate size and surface charge.

Authors:  Weiyu Chen; Huali Zuo; Timothy J Mahony; Bing Zhang; Barbara Rolfe; Zhi Ping Xu
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

6.  Population structure of Escherichia coli O26 : H11 with recent and repeated stx2 acquisition in multiple lineages.

Authors:  Yoshitoshi Ogura; Yasuhiro Gotoh; Takehiko Itoh; Mitsuhiko P Sato; Kazuko Seto; Shyuji Yoshino; Junko Isobe; Yoshiki Etoh; Mariko Kurogi; Keiko Kimata; Eriko Maeda; Denis Piérard; Masahiro Kusumoto; Masato Akiba; Kiyoshi Tominaga; Yumi Kirino; Yuki Kato; Katsuhiko Shirahige; Tadasuke Ooka; Nozomi Ishijima; Ken-Ichi Lee; Sunao Iyoda; Jacques Georges Mainil; Tetsuya Hayashi
Journal:  Microb Genom       Date:  2017-11

7.  Sequences of two related multiple antibiotic resistance virulence plasmids sharing a unique IS26-related molecular signature isolated from different Escherichia coli pathotypes from different hosts.

Authors:  Carola Venturini; Karl A Hassan; Piklu Roy Chowdhury; Ian T Paulsen; Mark J Walker; Steven P Djordjevic
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

8.  Evolution of enterohemorrhagic escherichia coli O26 based on single-nucleotide polymorphisms.

Authors:  Stefan Bletz; Martina Bielaszewska; Shana R Leopold; Robin Köck; Anika Witten; Jörg Schuldes; Wenlan Zhang; Helge Karch; Alexander Mellmann
Journal:  Genome Biol Evol       Date:  2013       Impact factor: 3.416

9.  Enterohemorrhagic Escherichia coli outbreaks related to childcare facilities in Japan, 2010-2013.

Authors:  Atsuhiro Kanayama; Yuichiro Yahata; Yuzo Arima; Takuri Takahashi; Takehito Saitoh; Kazuhiko Kanou; Kunio Kawabata; Tomimasa Sunagawa; Tamano Matsui; Kazunori Oishi
Journal:  BMC Infect Dis       Date:  2015-11-20       Impact factor: 3.090

10.  Community-wide outbreak of haemolytic uraemic syndrome associated with Shiga toxin 2-producing Escherichia coli O26:H11 in southern Italy, summer 2013.

Authors:  Cinzia Germinario; Alfredo Caprioli; Mario Giordano; Maria Chironna; Maria Serena Gallone; Silvio Tafuri; Fabio Minelli; Antonella Maugliani; Valeria Michelacci; Luisa Santangelo; Onofrio Mongelli; Cosimo Montagna; Gaia Scavia
Journal:  Euro Surveill       Date:  2016-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.